Breast cancer outcomes continue to improve due to increased awareness, early diagnosis and the introduction of novel therapies. However, there are challenges remaining for both clinicians and scientists, in particular in improving the outcome for patients’ triple negative and metastatic disease and in early detection. This meeting will cover the most recent developments in breast cancer research, with world-leading speakers providing a clinical and pre-clinical perspective to each topic. The programme includes new insights into the changing landscape of breast cancer therapies like the use of immunotherapy, CDK4/6 inhibitors, PARP inhibitors and how we can use new technologies like mathematical modelling and artificial intelligence to help improve patient care. There will also be a session focussed on DCIS, metabolomics and the role of the microbiome in breast cancer, as well as on how to study tumour cell dormancy and metastatic disease. In addition there will be a number of oral presentations selected from the submitted abstracts, offering junior investigators and students the opportunity to present their work to an expert audience. An evening program is focussed on the needs of early career researchers, how to involve patients in your research and how to obtain human tissue for your studies.
This meeting is a follow up to our successful 2015 meeting held at the same venue which was highly rated by the participants, and aims to bring together both clinicians and scientists with an interest in breast cancer research.
· Immunotherapy in breast cancer – where are we?
Regulation of tumour cell dormancy
Immunotherapy – use in breast cancer model systems
The science that paved the way for PARP inhibitors
Tumour cell dormancy and breast cancer recurrence
Mathematical Oncology – what it is and what it can do for you
Novel agents – CDK4/6 and PARP inhibitors and beyond
DCIS – recent developments in clinical research
Metabolomics – role in tumour progression and therapeutic response
DCIS – to treat or not to treat?
The microbiome in breast cancer – friend or foe?
· On the horizon - the next decade of breast cancer research
Why we should invest in breast cancer prevention
If you have any special dietary requirements - please let us know.
Your email address will be retained in our electronic registration database and used for correspondence from the BACR.
List of Participants
If you attend, we will include your name and country in the printed programme book unless you request to be removed.
Please click below if you agree for your email address to be included in the printed List of Participants that is given to all attendees and exhibitors.
Please note: you have selected for your email address NOT to appear in the List of Participants.
You can click above to change this.
BACR is a registered charity in England and Wales (289297)
c/o Leeds Institute of Medical Research at St James’s, Cancer Genetics Building,
St James's University Hospital, Beckett Street, Leeds LS9 7TF